ArticleBJS open2025
Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.
Article in BJS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPortal vein tumour thrombus (PVTT) significantly worsens the prognosis of hepatocellular carcinoma. Although combination therapy involving immune checkpoint inhibitors, anti-angiogenics, and locoregional treatment has shown promising anti-tumour activity, the comparative effectiveness of liver resection versus transarterial chemoembolization within such regimens remains unclear.
methodsThis multicentre, retrospective study enrolled patients with hepatocellular carcinoma and PVTT who received either liver resection or transarterial chemoembolization, each combined with PD-1 inhibitors and lenvatinib (LRPL and TPL, respectively), between 2019 and 2023. Survival outcomes were compared using the Kaplan-Meier method. Propensity score matching was applied to balance baseline characteristics and reduce potential confounding between the two groups.
resultsA total of 430 patients were included, and 155 patients remained in each cohort after 1:1 propensity score matching. The LRPL cohort showed significantly longer overall survival than the TPL cohort, with a median(interquartile range) overall survival of 34.0 (30.0-45.9) months versus 22.9 (19.3-31.2) months (hazard ratio 0.71, 95% confidence interval 0.53 to 0.95; P < 0.001). Subgroup analysis revealed that the overall survival benefit of LRPL was primarily observed in patients with PVTT limited to secondary branches (hazard ratio 0.36, 0.21 to 0.64; P < 0.001). In contrast, no significant difference was found when PVTT involved the primary branches or main trunk (hazard ratio 0.91, 0.68 to 1.41; P = 0.240).
conclusionsThe LRPL strategy was associated with superior survival compared with TPL, especially in patients with secondary branch PVTT, indicating its potential as the preferred therapeutic option for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.